Recent Updates
Recently added Catalysts

Diprosone

Phase 2FDA approved

Metastatic Colorectal Cancer | Small molecule | Other |Roche Holding AG|Trials Updated: Jul 31, 2012

Diprosone development status

FDA approval on record Oct 3, 2001
Approval holderSchering
ApplicationNDA017691
Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jun 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Diprosone clinical trials

Diprosone · 1 trial · 2 indications

Phase 2 1
NCT00910676Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor InhibitorsMetastatic Colorectal Cancer
COMPLETED30 Analytics
PHASE2COMPLETED
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Metastatic Colorectal Cancer
NCT0091067630
Unlock trial analytics

Study Endpoints

Primary Endpoints

To reduce by 30 % the frequency of folliculitis by a local corticotherapy beginning at the same time that the treatment by EGF-R inhibitors began
2 months of treatment by corticotherapy

Secondary Endpoints

To assess the frequency of grade I, II and III folliculitis under Cetuximab and under Erlotinib
2 months of treatment
To list the cutaneous side effects of the EGF-R inhibitors
2 months of treatment
To assess the patient quality of life with the DLQI questionnaire
2 months of treatment
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION

Treatment Arms

ArmTypeDescription
DIPROSONEEXPERIMENTAL -

Interventions

NameTypeDescription
DiprosoneDRUG* Start of treatment: as soon as the EGF-R inhibitors treatment begins * Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening * Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage. * Period of treatment: 8 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Indication of Cetuximab in patients with metastatic colorectal cancer in association or not with irinotecan, after failure of a chemotherapy treatment with Irinotecan OR * Indication of Erlotinib, in patients with metastatic Non-Small-Cell Lung Carcinoma, after failure of at l...

Countries:France
Unlock Eligibility Criteria

Competitive Landscape -Colorectal Cancer 366 trials (matched to "Metastatic Colorectal Cancer")

Top 20 of 80 competitors

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY7PHASE3Ipilimumab, Nivolumab, Adagrasib, Pumitamig, BMS-986340
Johnson & JohnsonJNJ5PHASE3Amivantamab, JNJ-89402638, JNJ-95437446
AbbVie, Inc.ABBV9PHASE3Telisotuzumab Adizutecan, ABBV-400, Azirkitug, Budigalimab, ABBV-253
Merck & Co., Inc.MRK12PHASE3Pembrolizumab, Calderasib, MK-4830, Sacituzumab tirumotecan
Pfizer Inc.PFE12PHASE3PF-08634404, Bevacizumab, Tucatinib, Trastuzumab, tisotumab vedotin
GSK plc Sponsored ADRGSK7PHASE3Dostarlimab, GSK4418959, GSK5460025
Exelixis, Inc.EXEL7PHASE3Zanzalintinib, Cabozantinib
Summit Therapeutics IncSMMT3PHASE3Ivonescimab
Amgen Inc.AMGN2PHASE3Sotorasib, Panitumumab, Bevacizumab-awwb
Agenus Inc.AGEN4PHASE3Balstilimab, Botensilimab, AGEN2034
Incyte CorporationINCY3PHASE3INCA33890, Ruxolitinib
Eli Lilly and CompanyLLY9PHASE2LY2157299, Olomorasib, Cetuximab, LY4066434, Gemcitabine
Genmab A/S Sponsored ADRGMAB2PHASE3Petosemtamab, GEN1042
AstraZeneca PLCAZN8PHASE2Volrustomig, Datopotamab deruxtecan, Rilvegostomig, FPI-2053, FPI-2107
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK6PHASE2fruquintinib
Novartis AG Sponsored ADRNVS8PHASE2Spartalizumab, Dabrafenib, trametinib, Opnurasib, TNO155
BioNTech SE Sponsored ADRBNTX3PHASE2Autogene cevumeran, Pumitamig, BNT314
Regeneron Pharmaceuticals, Inc.REGN2PHASE2Cemiplimab
Revolution Medicines, Inc.RVMD7PHASE1Elironrasib, Daraxonrasib, Zoldonrasib, RMC-5127
Jazz Pharmaceuticals Public Limited CompanyJAZZ2PHASE2Zanidatamab
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Roche Holding AG (RHHBY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with DCompanies A to ZEvery biotech and pharma company we track